MAZE (Maze Therapeutics) ROE % Adjusted to Book Value: -6.41% (As of Mar. 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $28.87
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics ROE % Adjusted to Book Value?

Maze Therapeutics MAZE +1.53% 14 ROE % Adjusted to Book Value is -6.41% as of Mar. 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Maze Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -27.80%. Maze Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 4.34. Maze Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -6.41%.

Maze Therapeutics ROE % Adjusted to Book Value Related Terms

Maze Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics ROE % Adjusted to Book Value Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 Negative Equity -103.98

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -23.71 -11.40 -6.54 -6.41

MAZE vs AVBP, DMRA, CAPR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Maze Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maze Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's ROE % Adjusted to Book Value falls into.


MAZE
14GF Score
Maze Therapeutics Inc MAZE
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics ROE % Adjusted to Book Value Calculation

Maze Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-598.95% / 5.76
=-103.98%

Maze Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-27.80% / 4.34
=-6.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -6.41% mean?
Maze Therapeutics (MAZE) has a ROE % Adjusted to Book Value of -6.41% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Maze Therapeutics and its competitors.
Is Maze Therapeutics' ROE % Adjusted to Book Value too high?
Maze Therapeutics' current ROE % Adjusted to Book Value is -6.41%. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' ROE % Adjusted to Book Value compare to AVBP and DMRA?
Maze Therapeutics' ROE % Adjusted to Book Value of -6.41% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current ROE % Adjusted to Book Value is -6.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current ROE % Adjusted to Book Value of -6.41%. The current ROE % Adjusted to Book Value is -6.41%. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current ROE % Adjusted to Book Value is -6.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.87
Price